NAS:TBPH (Cayman Islands)
Business Description
Theravance Biopharma Inc
NAICS : 325412
SIC : 2834
Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104
Compare
Compare
Traded in other countries / regions
0TB.Germany
•
TBPH.USA
Description
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. It develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.2 | |||||
| Equity-to-Asset | -0.97 | |||||
| Debt-to-Equity | -1.94 | |||||
| Debt-to-EBITDA | -15.08 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -6.16 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -10.7 | |||||
| 3-Year EBITDA Growth Rate | 19.4 | |||||
| 3-Year EPS without NRI Growth Rate | 10.4 | |||||
| 3-Year FCF Growth Rate | -11 | |||||
| 3-Year Book Growth Rate | -69.9 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.38 | |||||
| 9-Day RSI | 62.08 | |||||
| 14-Day RSI | 58.12 | |||||
| 6-1 Month Momentum % | -5.54 | |||||
| 12-1 Month Momentum % | -34.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.74 | |||||
| Quick Ratio | 4.74 | |||||
| Cash Ratio | 4.07 | |||||
| Days Sales Outstanding | 90.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -293.14 | |||||
| Net Margin % | -193.71 | |||||
| ROA % | -26.38 | |||||
| ROIC % | -97.06 | |||||
| ROC (Joel Greenblatt) % | -97.73 | |||||
| ROCE % | -16.21 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 13.6 | |||||
| EV-to-EBIT | -23.75 | |||||
| EV-to-EBITDA | -28.36 | |||||
| EV-to-Revenue | 24.32 | |||||
| EV-to-Forward-Revenue | 13.13 | |||||
| EV-to-FCF | -9.72 | |||||
| Earnings Yield (Greenblatt) % | -4.22 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:TBPH
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 52.386 | ||
| EPS (TTM) ($) | -1.36 | ||
| Beta | 0.42 | ||
| Volatility % | 57.29 | ||
| 14-Day RSI | 58.12 | ||
| 14-Day ATR ($) | 0.485893 | ||
| 20-Day SMA ($) | 9.1645 | ||
| 12-1 Month Momentum % | -34.78 | ||
| 52-Week Range ($) | 6.1 - 14.28 | ||
| Shares Outstanding (Mil) | 76.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Theravance Biopharma Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||